Cost-Effectiveness of Nivolumab in Combination with Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden- Analysis Using 28-Month Overall Survival from Checkmate 067

Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.261
https://www.valueinhealthjournal.com/article/S1098-3015(17)30595-8/fulltext
Section Title : Disease-Specific Studies
Section Order : 239
First Page : A444
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30595-8&doi=10.1016/j.jval.2017.08.261
HEOR Topics :
Tags :
Regions :